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Objectives. The goal of this study was to examine the relative
safety and efficacy of laser-facilitated percutaneous transluminal
coronary angioplasty (PTCA) versus “stand-alone” PTCA.
Background. Plaque debulking with lasing before PTCA may
result in improved lumen dimensions and decreased rates of
periprocedural ischemic complications, thus improving short-
and long-term outcomes after percutaneous intervention. The
mid-infrared holmium:yttrium-aluminum-garnet (YAG) laser has
been shown to be effective in a variety of plaque subtypes and may
be particularly useful in high risk acute ischemic syndromes.
Methods. A total of 215 patients (mean [6SD] age 61 6 12
years) with 244 lesions were prospectively randomized at 14
clinical centers to laser versus stand-alone PTCA. After laser
treatment, all patients underwent PTCA; 148 patients (69%) had
unstable angina.
Results. The procedural success rate without major catheter-
ization laboratory complications was similar in patients assigned
to laser treatment or PTCA alone (96.6% vs. 96.9%, p 5 0.88), as
was the in-hospital clinical success rate (89.7% vs. 93.9%, p 5
0.27). There was no difference in postprocedural diameter stenosis
after laser treatment compared with PTCA (18.3% 6 13.6% vs.
19.5% 6 15.1%, p 5 0.50). However, use of the laser, versus PTCA
alone, did result in significantly more major and minor proce-
dural complications (18.0% vs. 3.1%, p 5 0.0004), myocardial
infarctions (4.3% vs. 0%, p 5 0.04) and total in-hospital major
adverse events (10.3% vs. 4.1%, p 5 0.08). At a mean follow-up
time of 11.2 6 7.7 months, there were no differences in late or
event-free survival in patients assigned to laser treatment versus
PTCA alone.
Conclusions. Compared with stand-alone PTCA, laser-
facilitated PTCA results in a more complicated hospital course,
without immediate or long-term benefits.
(J Am Coll Cardiol 1997;30:1714–21)
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Despite advances in equipment and technique, percutaneous
transluminal coronary angioplasty (PTCA) continues to be
associated with an approximate 4% to 10% risk of major
periprocedural complications and a 30% to 50% likelihood of
angiographic restenosis within 6 months, which frequently
necessitates late repeat revascularization procedures (1–5). By
removing plaque before balloon dilation, debulking tech-
niques, such as laser or atherectomy, may potentially diminish
the rate of PTCA-induced major dissection and complications
and improve late angiographic and clinical outcomes. In this
regard, both the excimer and holmium lasers have been shown
in large, prospective registry experiences to have favorable
success rates in most lesion subtypes compared with balloon
angioplasty (6–10). We therefore performed a prospective,
randomized, multicenter trial to examine the acute and late
outcomes of laser-facilitated PTCA versus standard PTCA.
Methods
Patients and clinical centers. To examine the short- and
long-term outcomes of holmium laser-facilitated balloon an-
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gioplasty versus “stand-alone” PTCA, 14 centers experienced
in the use of the Eclipse Holmium 2100 laser entered patients
in a prospective, randomized trial. The primary end point was
the 6-month composite incidence of freedom from death,
myocardial infarction (MI) or need for coronary artery bypass
graft surgery or repeat PTCA. With an alpha error of 0.05 and
a beta error of 0.20, 190 randomized patients with complete
follow-up were required to show an improvement in the
primary end point from an expected rate of 70% after stand-
alone PTCA to 85% after laser-facilitated PTCA.
Entry criteria were nonrestrictive and included patients
$18 years old, with no upper age limit, with primary or
restenotic lesions in a native coronary artery or saphenous vein
bypass graft. The first 10 sites enrolled patients with stable or
unstable angina. After the demonstration that the holmium
laser may be particularly effective in patients with acute
ischemic syndromes (7,11,12), an additional four sites were
added that randomized patients with unstable angina only.
Patients presenting with an acute MI within 24 h of the
procedure were excluded. Patients were also excluded for
specific laser contraindications, including an index lesion that
was on a bend .60°, if the reference segment was ,2.0 mm in
diameter or if excessive proximal tortuosity or heavy calcifica-
tion was present, making it unlikely that the catheter could be
delivered to or cross the stenosis. The presence of a chronic
total occlusion was not an exclusion criteria itself; however,
randomization occurred only after the lesion was successfully
crossed with a guide wire, and thus nonrecanalizable total
occlusions were excluded. This protocol was approved by the
Food and Drug Administration (FDA) as part of the regula-
tory pathway for market authorization for the holmium laser.
Written informed consent was obtained from all patients
before enrollment after local investigational review board
approval.
Study protocol. Patients were pretreated with $324 mg of
aspirin daily for $24 h and calcium channel blocking agents.
Other medications before cardiac catheterization were dic-
tated by clinical presentation. After left ventriculography and
coronary arteriography, if suitable coronary anatomy was
present for study entry, randomization occurred by opening a
sealed envelope after the index lesion was successfully wired. If
multiple target lesions were present, all lesions must have met
entry criteria and were approached by the assigned modality.
Intravenous heparin was administered to maintain an activated
clotting time .350 s. Intracoronary nitroglycerin ($100 mg)
was given before intervention. If randomization was to PTCA,
balloons were chosen to approximate the reference vessel size,
and dilation was performed with a goal of #30% residual
stenosis without major dissection. If randomization was to
laser treatment, lasing was performed as described in the next
section, followed by PTCA in all patients to maximize the final
lumen dimension. After the procedure, the sheaths were
removed in 6 to 12 h, and patients were discharged when in
clinically stable condition. Calcium channel blockers were
prescribed for 1 month and aspirin indefinitely. Clinical
follow-up was scheduled for 1, 3 and 6 months after the
procedure.
Laser system and procedure. The holmium:yttrium-
aluminum-garnet (YAG) Eclipse 2100 (Eclipse Surgical Tech-
nologies) is a pulsed, solid state, mid-infrared laser that has
been used in 1,862 patients since 1990 under an Investigational
Device Exemption (IDE) from the FDA. Laser light with a
wavelength of 2.09 mm is transmitted through multiple optical
low OH flexible silica fibers and emitted from the distal tip of
the catheter after foot pedal activation. The device delivers
5 pulses/s with a pulse duration of 250 ms with an energy range
of 250 to 1,000 mJ/pulse (1.25 to 5.0 W). The energy density
(fluence) at the tip of the catheter is 125 to 500 mJ/mm2 per
pulse. The tissue penetration depth is 400 mm. Six different
catheter sizes (1.2, 1.3, 1.4, 1.5, 1.7 and 2.0 mm) are manufac-
tured that vary in diameter, number of fibers per catheter and
flexibility. The 1.2- to 1.5-mm diameter catheters are compat-
ible with an 8F guide catheter, whereas the larger devices
require a 9F guide. All catheters traverse over a 0.014-in. guide
wire.
The choice of laser variables (catheter size and energy
range) was left to the discretion of the operator. In general, the
smaller diameter catheters are initially chosen for severe
lesions. The laser is prepared by flushing the central guide wire
lumen and connecting the proximal end to the laser console.
The device is then turned on and left in standby mode. No
warm-up period or other calibrations are required. The cath-
eter is then passed over the guide wire just proximal to the
lesion and placed in active mode. The “pulse and retreat”
technique is used for crossing the lesion (13), in which only a
small number of pulses, usually 8 to 12 per session, are used
with gentle forward pressure being applied to the catheter
under fluoroscopy. The catheter is then withdrawn into the
proximal artery or guide catheter for 30 to 60 s to allow heat
dissipation and gas bubble dispersion. The catheter is then
readvanced to the lesion, and serial passes are made with
similar technique. Typically, lower energy fluences are initially
selected and are then increased if adequate ablation is not
occurring. Repeat arteriography, after intracoronary nitroglyc-
erin, was performed after the last laser pass. The maximal laser
catheter diameter and fluence, total number of pulses and total
lasing time were recorded.
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American Heart
Association
AMRO 5 Amsterdam–Rotterdam (trial)
CK 5 creatine kinase
ECG 5 electrocardiogram
FDA 5 Food and Drug Administration
LAVA 5 Laser Angioplasty Versus Angioplasty (trial)
MI 5 myocardial infarction
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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Definitions. Unstable angina was defined as new-onset,
crescendo, rest or postinfarction angina. For the purpose of
this study, laser success was defined as the ability of the laser to
completely cross the lesion and reduce the stenosis by $20%.
Procedural success was defined as ,50% residual stenosis after
PTCA, without major catheterization laboratory complication
(death, emergency bypass surgery or sustained coronary occlu-
sion). Anterograde flow was assessed by the Thrombolysis in
Myocardial Infarction (TIMI) scale (14). Lesion morphology
was characterized by the modified American College of Car-
diology/American Heart Association (ACC/AHA) score (15).
Thrombus was defined as an intraluminal filling defect, lucency
or haziness refractory to intracoronary nitroglycerin. Coronary
spasm was defined as transient reduction in blood flow with
vessel caliber narrowing relieved either spontaneously or by
nitroglycerin. Abrupt closure was defined as sustained TIMI
flow grade 0 to 1 caused by obstruction of the target lesion. Q
wave MI was defined as elevation of creatine kinase (CK) levels
greater than two times above laboratory normal values with
any abnormal MB fraction and the development of new
pathologic Q waves on the electrocardiogram (ECG). A non-Q
wave MI was defined as the development of similar CK
elevations without Q waves. Clinical success was defined when
a residual stenosis ,50% was obtained, and the patient
survived the hospital period without an MI (Q wave or non Q
wave) or need for repeat PTCA or bypass surgery.
Data collection and statistical analysis. Detailed in-
hospital and 1- and 6-month follow-up case report forms were
prospectively completed for each patient and confirmed by
review of catheterization reports, ECGs laboratory tests and
discharge summaries. A study monitor traveled to each site for
independent verification of case report form accuracy. Adverse
events were reported to the clinical coordinating center within
24 h of occurrence. Angiograms were evaluated by individual
operators using digital calipers or visual assessment. Data was
entered into a computerized database, and statistical analysis
was performed with commercially available packages (Statview
4.5, Abacus Concepts and JMP 3.1, SAS Institute). Intention to
treat analysis was performed. Categoric variables were com-
pared with chi-square or Fisher exact tests, and continuous
variables were compared with an unpaired Student t test. To
determine the independent correlates of procedural and clin-
ical success, several variables known to affect outcomes were
entered into a multiple logistic regression model (age, gender,
diabetes, triple-vessel disease, treatment of any thrombotic
lesion, any total occlusion, any ACC/AHA class C lesion,
reference vessel size ,3.0 mm or $3.0 mm in diameter, as well
as randomization arm). Follow-up events were analyzed with
actuarial methods, and Kaplan-Meier curves were constructed.
Differences in late events among patients undergoing laser
angioplasty versus stand alone PTCA were compared with the
log rank test. Variables affecting late and event-free survival
were examined using Cox proportional hazards regression
analysis. A p value ,0.05 was required for statistical signifi-
cance.
Results
Patients. A total of 215 patients were randomized at 14
centers, with 244 lesions treated. There were no major differ-
ences in baseline demographic characteristics in patients as-
signed to laser or standard PTCA, except for a higher inci-
dence of previous MI in laser-treated patients (Table 1).
Baseline angiographic characteristics were also well matched
among the two treatment groups, except that lesions assigned
to laser treatment were more likely to have thrombus present
(Tables 2 and 3).
Table 1. Baseline Clinical Characteristics of 215 Study Patients
Laser
(n 5 117)
PTCA
(n 5 98)
p
Value
Age (yr) 60.3 6 11.3 62.8 6 12.5 0.14
Female gender 31.6% 30.6% 0.78
Hypertension 59.8% 59.2% 0.87
Hypercholesterolemia 48.2% 46.8% 0.91
Diabetes mellitus 19.7% 27.6% 0.22
Cigarette use 57.2% 54.6% 0.65
Silent ischemia 3.4% 5.1% 0.76
Chronic stable angina 27.4% 26.5% 0.82
Unstable angina 69.2% 68.4% 0.89
Pain only with MI 12.0% 17.4% 0.26
Postinfarction angina 9.4% 3.1% 0.09
Prior MI 53.8% 35.7% 0.008
Prior CHF 6.0% 8.2% 0.53
Prior PTCA 27.4% 33.7% 0.29
Prior CABG 10.3% 12.2% 0.63
Data presented are mean value 6 SD or percent of patients. CABG 5
coronary artery bypass graft surgery; CHF 5 congestive heart failure; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Baseline Angiographic Characteristics of 244 Treated
Lesions in 215 Patients
Laser PTCA p Value
Patients n 5 117 n 5 98
LVEF (%) 55 6 12 54 6 11 0.41
No. of diseased epicardial vessels
1 61.5% 66.3% 0.47
2 28.2% 19.4% 0.13
3 10.3% 14.3% 0.37
Lesions n 5 125 n 5 119
IRA distribution
LAD 26.0% 30.7% 0.42
LCx 24.4% 42.1% 0.62
RCA 49.6% 27.2% 0.25
Infarct lesion location
Proximal vessel 29.3% 31.6% 0.70
Midvessel 43.1% 36.8% 0.33
Distal vessel or branch 27.6% 31.6% 0.51
Data presented are mean value 6 SD or number or percent of patients or
lesions. IRA 5 infarct-related artery; LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex coronary artery; LVEF 5 left ventricular ejection
fraction; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right
coronary artery.
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Procedural outcome. Among patients randomized to laser
angioplasty, the laser catheter reached the lesion and was
activated in 122 (98%) of 125 lesions. Laser success was
achieved in 117 lesions (93.6%), whereas the laser partially
penetrated the lesion in 3 lesions (2.4%). Mean (6SD) cath-
eter size was 1.3 6 0.2 mm, and a mean of 1.1 6 0.3 catheters
were used per patient. A mean of 103 6 294 pulses were
applied per lesion, at maximal mean energy of 3.1 6 0.5 W.
PTCA was performed in all patients assigned to laser treat-
ment. Reference vessels were judged to be slightly larger in the
laser-treated patients than the PTCA-treated patients. This
difference was compensated for by use of larger balloons in
patients assigned to laser treatment, and thus the balloon/
artery ratio was identical between the two groups (Table 4).
There were no other significant differences in PTCA variables
in patients randomized to laser-facilitated versus stand-alone
PTCA (Table 4).
The results of the quantitative angiographic analysis are
shown in Table 5. By on-site assessment, baseline lesion
severity was slightly worse in patients assigned to laser angio-
plasty than in those with stand-alone PTCA. However, there
was no difference in the final post-PTCA residual stenosis
between the two groups, although the absolute minimal lumen
diameter was slightly greater in the laser-treated patients,
given the larger baseline mean reference vessel diameter.
Dissection was noted in only 5.6% of patients immediately
after laser treatment. However, the frequency of dissection
after laser-facilitated PTCA was similar to that after stand-
alone PTCA (16.8% vs. 15.9%, respectively, p 5 0.85).
Procedural success without major catheterization labora-
tory complications was obtained in 96.6% of laser-treated
patients versus 96.9% of PTCA-treated patients (p 5 0.88).
The only variable independently predictive of procedural
failure in the multivariate model was the presence of triple-
vessel disease (odds ratio [OR] 6.3, p 5 0.03). However, as
shown in Table 6, procedural complications were significantly
Table 3. Baseline Angiographic Lesion Morphology
Laser
(n 5 125)
PTCA
(n 5 119)
p
Value
ACC/AHA classification
A 13.6% 25.2%
B1 16.8% 16.8%
0.16
B2 55.2% 46.2%
C 14.4% 11.8%
Lesion length (mm) 11.9 6 6.6 11.2 6 6.7 0.46
.10 mm 43.5% 42.4% 0.79
Eccentric 52.0% 43.2% 0.17
Proximal tortuosity 27.2% 21.2% 0.52
Angulated segment .45° 6.5% 12.1% 0.27
Irregular contour 52.4% 43.6% 0.17
Calcification present 17.1% 13.6% 0.45
Total occlusion 9.6% 5.0% 0.18
Ostial location 0.8% 2.5% 0.36
Bifurcation lesion 4.0% 5.9% 0.48
Thrombus present 26.8% 14.4% 0.02
Degenerated saphenous vein graft 1.6% 0% 0.55
Data presented are mean value 6 SD or percent of lesions. ACC/AHA 5
American College of Cardiology/American Heart Association; PTCA 5 percu-
taneous transluminal coronary angioplasty.
Table 4. Coronary Angioplasty Variables for 244 Lesions
Laser
(n 5 125)
PTCA
(n 5 119)
p
Value
Balloons/lesion 1.4 6 06 1.5 6 0.9 0.30
Inflations/lesion 3.1 6 2.1 3.3 6 2.8 0.55
Ref seg diam (mm) 3.1 6 0.4 2.9 6 0.4 0.008
Max balloon size (mm) 3.1 6 0.5 2.9 6 0.4 0.009
Balloon/artery ratio 1.0 6 0.1 1.0 6 0.1 0.79
Total inflation time (min) 7.8 6 7.0 8.6 6 7.7 0.50
Max pressure (atm) 7.7 6 2.9 7.9 6 2.6 0.48
Data presented are mean value 6 SD. Max 5 maximal; PTCA 5 percuta-
neous transluminal coronary angioplasty; Ref seg diam 5 reference segment
diameter.
Table 5. Quantitative Angiographic Analysis
Laser
(n 5 125)
PTCA
(n 5 119)
p
Value
Ref seg diam (mm) 3.1 6 0.4 2.9 6 0.4 0.008
MLD (mm)
Before intervention 0.3 6 0.3 0.4 6 0.4 0.01
After laser 1.0 6 0.6 — —
After PTCA 2.5 6 0.5 2.3 6 0.6 0.04
%DS
Before intervention 89.6 6 9.0 85.8 6 11.7 0.005
After laser 67.0 6 16.5 — —
After PTCA 18.3 6 13.6 19.5 6 15.1 0.50
Data presented are mean value 6 SD. MLD 5 minimum lumen diameter;
%DS 5 percent diameter stenosis; — 5 not applicable; other abbreviations as in
Table 4.
Table 6. Periprocedural Complications in 215 Patients
Laser
(n 5 117)
PTCA
(n 5 98)
p
Value
Major complications
Coronary occlusion 5.1% 2.0% 0.30
Emergency CABG 1.7% 0 0.50
Sustained VT/VF 0.9% 0 0.65
Cardiopulmonary arrest 0 0 —
Free perforation with tamponade 0 0 —
Stroke 0 0 —
Death 0 0 —
Any major complication 6.8% 2.0% 0.11
Minor complications
Coronary artery spasm 9.4% 1.0% 0.007
New thrombus formation 4.3% 1.0% 0.10
Distal thromboembolism 0.9% 0 0.65
Localized perforation without
tamponade
1.7% 0 0.50
Any minor complication 14.0% 2.0% ,0.0001
Any procedural complication
(major or minor)
18.0% 3.1% 0.0004
Data presented are percent of patients. VT/VF 5 ventricular tachycardia/
ventricular fibrillation; other abbreviations as in Tables 1 and 5.
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more frequent in patients undergoing laser treatment than
stand-alone PTCA. By multivariate analysis, the only correlate
predictive of procedural complications was randomization to
laser treatment (OR 7.5, p 5 0.002).
In-hospital and late clinical events. Overall clinical success
in patients randomized to laser-facilitated PTCA was similar to
that in patients with stand-alone PTCA (89.7% vs. 93.9%,
respectively, p 5 0.39). In-hospital adverse events are pre-
sented in Table 7, and tended to occur more frequently in the
laser-treated group. Postprocedural MI was more common in
laster-treated patients than in those managed with PTCA only.
Late follow-up was available in 209 (99%) of 212 patients
discharged alive at a mean time of 11.2 6 7.7 months. By
actuarial analysis, there was no difference in long-term rates of
mortality, MI or reintervention in patients treated with laser
versus PTCA alone, whether adverse in-hospital events were
included (Fig. 1) or excluded (Fig. 2) in the determination. By
Cox regression analysis, only the presence of triple-vessel
disease was identified as an independent correlate of late
death, MI or repeat revascularization (OR 2.4, p 5 0.009).
Patients with previous MI and thrombus-containing le-
sions. Because patients randomized to laser treatment had a
higher baseline incidence of previous MI and lesions contain-
ing thrombus than did patients randomized to PTCA only,
separate analyses were performed in these subgroups. When
considered independently of the randomization arm, previous
MI was not a correlate of cumulative 6-month adverse events
(death, MI, bypass surgery or repeat PTCA) (24.5% in patients
with vs. 28.2% in those without a previous MI, p 5 0.90).
Similarly, treatment of a thrombus-containing lesion had no
effect on the occurrence of cumulative 6-month adverse events
(29.0% in patients undergoing treatment of one or more
lesions with thrombus vs. 25.7% in patients with no lesions with
thrombus, p 5 0.68). Furthermore, no major differences in
acute or late outcomes in patients treated with laser versus
stand-alone PTCA substratified by these baseline differences
were identified (Table 8).
Discussion
Previous studies. Only one prospective, randomized study
(16) has been previously published in which the strategy of
plaque debulking with a laser before PTCA was directly
compared with stand-alone PTCA. In the multicenter Amster-
dam–Rotterdam (AMRO) trial (16), 308 patients with stable
angina and lesions visually .10 mm in length were randomized
to excimer laser angioplasty (followed by PTCA in 98% of
patients) versus PTCA only (16). There were no differences in
acute or late major clinical events between the two groups. By
Table 7. Major In-Hospital End Points (includes cardiac
catheterization laboratory events)
Laser
(n 5 117)
PTCA
(n 5 98)
p
Value
Death 1.7% 0% 0.50
CABG 2.6% 3.1% 0.83
Emergent 1.7% 0% 0.50
Urgent 0.9% 2.1% 0.59
Elective 0% 1.0% 0.46
MI 4.3% 0% 0.04
Q wave 0.9% 0% 0.65
Non-Q wave 3.4% 0% 0.12
Repeat PTCA 7.0% 3.1% 0.19
Any major adverse event* 10.3% 4.1% 0.08
Duration of hospital stay (days) 5.1 6 3.9 4.3 6 3.8 0.15
*Death, Q wave or non-Q wave myocardial infarction (MI), coronary artery
bypass graft surgery (CABG) or repeat percutaneous transluminal coronary
angioplasty (PTCA). Data presented are mean value 6 SD or percent of
patients.
Figure 1. Kaplan-Meier curves displaying
cumulative survival and event-free survival
in patients randomized to undergo laser-
facilitated PTCA (triangles) versus stand-
alone PTCA (circles). Outcomes include
in-hospital and late events. Inset in each
graph are the 6- and 12-month survival rates
by actuarial analysis, with the corresponding
p values by the log rank test. CABG 5
coronary artery bypass graft surgery.
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quantitative coronary analysis, similar acute gain was realized
after both strategies, but late loss was greater in the laser-
treated patients. As a result, restenosis tended to be greater
after laser angioplasty than after PTCA alone (52% vs. 41%,
p 5 0.13).
Compared with the ultraviolet excimer laser, the mid-
infrared holmium laser offers several advantages that war-
ranted a second randomized trial of somewhat different design:
1. The holmium laser may result in less arterial damage
than the excimer laser, a contention supported by registry data
(6–9,17). Both the excimer and holmium lasers produce pho-
toacoustic trauma by the creation, rapid expansion and disper-
sion of vapor gas bubbles that can result in arterial dissection
or perforation (18–20). Although the extent of dissection may
be reduced by replacing the blood field with saline before
excimer treatment (21), a histologic comparative in vitro study
(22), in which presently available catheters at clinically relevant
energy levels and pulse strategies were used, found that the
holmium laser resulted in fewer arterial cleavage planes (dis-
sections) than did the excimer laser, despite lasting in a saline
field.
2. Thrombi, which possess a high water content, avidly
absorb light in the mid-infrared region (23). As a result, the
holmium laser has been found to be particularly effective in
thrombus-containing lesions and acute ischemic syndromes
(7,11,12). In contrast, lower success and greater complication
rates have been reported after treatment of thrombotic lesions
with the excimer laser (24). These observations were incorpo-
rated into the design of both the AMRO and Laser Angio-
plasty Versus Angioplasty (LAVA) trials. Whereas the AMRO
study excluded patients with unstable angina and thrombus-
containing lesions, the present trial was specifically weighted to
capture these patient subgroups. The solid state design of the
mid-infrared laser confers other advantages of this system
compared with the excimer, including short warm-up times,
minimal maintenance, a smaller footprint, no toxic gases to
vent and lower cost (6,23,24).
Results of the present study. Despite these considerations,
no acute or late benefits of holmium laser-facilitated PTCA
versus stand-alone PTCA were found in the present random-
ized trial, either by univariate or multivariate analysis. Laser
success was relatively improved when treating thrombus-
containing lesions but still did not surpass PTCA alone. In
contrast, procedural complications were significantly increased
Figure 2. Kaplan-Meier curves displaying
survival and event-free survival after hospi-
tal discharge (excluding in-hospital events)
in patients randomized to undergo laser-
facilitated PTCA (triangles) versus stand-
alone PTCA (circles). Format as in Figure
1. CABG 5 coronary artery bypass graft
surgery.
Table 8. Comparison of Outcomes in Laser- and Coronary Angioplasty-Assigned Patients Substratified by Presence of Previous Myocardial
Infarction and Lesional Thrombus
Previous MI No Previous MI $1 Lesion With Thrombus No Lesion With Thrombus
Laser
(n 5 63)
PTCA
(n 5 35)
p
Value
Laser
(n 5 54)
PTCA
(n 5 63)
p
Value
Laser
(n 5 32)
PTCA
(n 5 17)
p
Value
Laser
(n 5 85)
PTCA
(n 5 81)
p
Value
Procedural success 96.8% 97.1% 0.93 96.3% 96.8% 0.88 96.9% 100% 0.65 96.5% 96.3% 0.95
Clinical success 90.5% 97.1% 0.22 88.9% 92.1% 0.55 87.5% 88.2% 0.94 90.6% 95.1% 0.26
6-mo EFS 73.9% 78.8% 0.78 67.8% 75.3% 0.49 71.7% 69.3% 0.99 70.8% 78.0% 0.46
Data presented are percent of patients. EFS 5 event-free survival (survival free from myocardial infarction [MI], bypass surgery or repeat percutaneous
transluminal coronary angioplasty [PTCA]; includes in-hospital events).
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by lasing before PTCA, especially the occurrence of spasm,
with trends noted for greater abrupt coronary occlusion and
new thrombus formation. As a result, the rate of periproce-
dural MI was increased, and trends were present for greater
overall major complications and a longer hospital stay. Thus,
the present trial does not support the use of laser angioplasty
as an everyday tool, even in high risk patients with unstable
angina or thrombus-containing lesions (2,25), especially when
the high costs of the system and single-use catheters are
factored into account. The negative results of the LAVA and
AMRO trials, in direct contradiction to the earlier favorable
registry experiences, reconfirm the essential importance of
performing prospective, multicenter, randomized trials before
the widespread adoption of new methodologies can be recom-
mended.
Limitations of the study. Several limitations of this study
must be acknowledged: 1) Given the relatively small sample
size, the study was powered to show only major differences
between the two treatment arms. Lesser degrees of benefit
favoring laser-assisted PTCA or stand-alone PTCA may have
gone undetected. However, given the higher rate of complica-
tions and slightly worse long-term outcomes with lasing in this
trial, it is unlikely that enrolling a larger population would have
revealed significant long-term benefits in the laser arm. 2)
Although the two treatment arms were well matched for most
baseline characteristics, several differences were present be-
tween the two groups, including the frequency of previous MI
and the presence of thrombus-containing lesions. However,
when analyzed separately and adjusted for by multivariate
analysis, these factors had no bearing on acute or late event-
free survival. 3) Some degree of selection bias cannot be
excluded, especially in investigator reporting of clinical events
and angiographic results. However, the participating physi-
cians were dedicated laser investigators, suggesting that bias, if
present, would have been directed toward more favorable laser
results. 4) The results of the angiographic analysis must be
cautiously regarded, given the lack of a central core laboratory.
However, the lack of any difference in the site-assessed final
percent diameter stenoses between the laser and stand-alone
PTCA groups suggests that no true angiographic benefit of
laser is likely to exist. Furthermore, the equivalent 6-month
clinical outcomes between the two treatment groups are con-
sistent with the nearly identical acute lumen outcomes ob-
served (26).
Finally, and perhaps most importantly, the size of the laser
catheters used in the present trial (and the AMRO study), in
concert with the observation that laser angioplasty results in
minimal plaque debulking, may have made the comparative
late outcomes after laser-facilitated angioplasty versus stand-
alone PTCA a fait accompli. Recent studies have demon-
strated that if debulking is to reduce restenosis and improve
late clinical events, it is likely to do so by improving the acute
result obtained (26). However, studies with intravascular ultra-
sound imaging have shown that with present-day catheters and
techniques, laser debulking of plaque contributes only a small
percentage of the lumen gain realized after adjunctive PTCA
(27). In the present trial, with a mean catheter size of 1.3 mm
used, the average cross-sectional area stenosis after laser alone
would be expected to be 81% (assuming 100% ablation
efficiency and no significant vessel remodeling). However,
given the high rate of procedural complications noted with the
small diameter catheters utilized in this study, it is doubtful
that the use of larger catheters to achieve more complete
plaque removal would be safe. The important issue of whether
maximal plaque debulking improves long-term outcomes after
percutaneous intervention is being addressed with regard to
high speed rotational atherectomy in the ongoing Study to
Determine Rotablator and Transluminal Angioplasty Strategy
(STRATUS) trial.
Present role of laser coronary angioplasty. In view of the
results of the present trial, which confirm and extend the
AMRO study findings, the routine use of laser angioplasty
before PTCA is unwarranted. Whether laser facilitation of
balloon angioplasty is or is not useful for lesions that are
known to respond poorly to PTCA, such as ostial lesions,
bifurcation stenoses, undilatable lesions and in-stent restenosis
(10,28), cannot be answered by these trials because too few
patients with these lesion characteristics were included. How-
ever, many of these lesion subtypes also respond well to high
speed rotational atherectomy, which is potentially a more
cost-effective alternative, given the high up-front costs of the
laser system. A unique role for lasers in coronary artery disease
may yet be found with the laser wire application to recanalize
chronic total occlusions that cannot be traversed by conven-
tional guide wires (29).
Appendix
Participating Institutions and Investigators for the
Laser Angioplasty Versus Angioplasty Trial
Clinical Coordinating Center. The Cardiovascular Institute, El Camino
Hospital, Mountain View, California: Gregg W. Stone (Primary Investigator),
JoAnn McDonnell, Nancy Richardson.
Clinical Centers and Principal Investigators. The University of Miami/
Jackson Memorial Hospital, Miami, Florida: Eduardo de Marchena. Audubon
Hospital, Louisville, Kentucky: David Dageforde, Richard Allen. St. Francis
Hospital, Evanston, Illinois: Alberto Foschi, Alan Kogan. LDS Hospital, Salt Lake
City, Utah: Joseph B. Muhlestein. All Children’s Hospital, St. Petersburg, Florida:
Michael McIvor. Scottsdale Memorial Hospital, Scottsdale, Arizona: David Rizik.
Blodgett Memorial Medical Center, Grand Rapids, Michigan: Ronald Vanderlann,
Ray Roden. The Cleveland Clinic Foundation, Cleveland, Ohio: Joe Sutton.
Episcopal Heart Institute, Philadelphia, Pennsylvania: Vidya Banka, Peter Fail.
Maimonides Medical Center, Brooklyn, New York: Robert Frankel, Jacob Shani.
Methodist Hospital, Indianapolis, Indiana: Kirk Parr. Rex Hospital, Raleigh, North
Carolina: Daryl Emery. Texas Heart Institute, Houston, Texas: Emerson Perin.
University Medical Center, Tucson, Arizona: Samuel Butman.
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